Abstract:Magnetic resonance imaging (MRI), one of the most general imaging techniques in the clinic, is widely employed for tumor diagnosis with the assistance of contrast agents (CAs). However, currently available CAs in the clinic suffer from shortcomings of a short blood circulation time, lack of specificity to pathological location, insufficient imaging window, and potential biotoxicity of the gadolinium ion. To overcome these problems, on the basis of extremely small iron oxide nanoparticles (ESIONPs), a hypoxia-responsive T1-to-T2 switchable MRI contrast agent was designed and constructed. In detail, polyacrylic acid-modified ESIONPs (ESIONPs-PAA) were first synthesized, and then, nitroimidazole derivatives and cysteine molecules were sequentially coupled on the surface of ESIONPs-PAA to obtain a hypoxia-responsive MRI contrast agent (HR-ESIONPs). Since 2-nitroimidazole and cysteine molecules on the surface of HR-ESIONPs can form an irreversible bond induced by the nitroreductase in the hypoxic tumor microenvironment, monodispersed HR-ESIONPs could transform into the nanocluster form, which can specially provide T2 contrast enhancement. In vitro experiments show that monodispersed HR-ESIONPs could effectively aggregate in the mimical hypoxic environment of tumors and switch from a T1 to T2 contrast agent. Moreover, in vivo experiments further confirm that HR-ESIONPs could effectively accumulate and realize the MRI signal switch from T1 to T2 contrast enhancement in tumors originating from the aggregation of HR-ESIONPs induced by the hypoxic environment, which promotes the diagnostic precision of tumors. Additionally, with the confirmation of favorable biosafety on cells and mice, hypoxia-responsive HR-ESIONPs are potential platforms to improve the diagnostic accuracy and sensitivity of MRI for tumors.

Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging.

Octapod iron oxide nanoparticles as high-performance T 2 contrast agents for magnetic resonance imaging

One pot synthesis of zwitteronic 99mTc doped ultrasmall iron oxide nanoparticles for SPECT/T1-weighted MR dual-modality tumor imaging

Exerting Enhanced Permeability and Retention Effect Driven Delivery by Ultrafine Iron Oxide Nanoparticles with T1-T2 Switchable Magnetic Resonance Imaging Contrast

Cubic Zinc-Doped Iron Oxide Nanoparticles with Poly(Ethylene Glycol) or Sodium Citrate Surface Coatings for Tumor Imaging

Targeted Dual-Contrast T1- and T2-weighted Magnetic Resonance Imaging of Tumors Using Multifunctional Gadolinium-Labeled Superparamagnetic Iron Oxide Nanoparticles

Extremely Small Iron Oxide Nanoparticle-Encapsulated Nanogels As a Glutathione-Responsive T1 Contrast Agent for Tumor-Targeted Magnetic Resonance Imaging

Transition metal doped hydrophilic ultrasmall iron oxide modulate MRI contrast performance for accurate diagnosis of orthotopic prostate cancer

Fe3O4 Nanoparticles Functionalized with Polymer Ligand for T-1-Weighted MRI in Vitro and in Vivo

Gd(III) complex conjugated ultra-small iron oxide as an enhanced T1-weighted MR imaging contrast agent

Single-Atom Gadolinium Nano-Contrast Agents with High Stability for Tumor <i>T</i><sub>1</sub> Magnetic Resonance Imaging

Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T1- and T2-weighted magnetic resonance imaging.

Engineered magnetic hybrid nanoparticles with enhanced relaxivity for tumor imaging

99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast ( T 1 / T 2 ) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis

Pegylated Hybrid Ytterbia Nanoparticles As High-Performance Diagnostic Probes for in Vivo Magnetic Resonance and X-Ray Computed Tomography Imaging with Low Systemic Toxicity

PET/NIRF/MRI triple functional iron oxide nanoparticles.

Single-Atom Gadolinium Nano-Contrast Agents with High Stability for Tumor T 1 Magnetic Resonance Imaging

Gadolinium (III)-Chelated Deformable Mesoporous Organosilica Nanoparticles as Magnetic Resonance Imaging Contrast Agent.

Ultrasmall gadolinium hydrated carbonate nanoparticle: An advanced T 1 MRI contrast agent with large longitudinal relaxivity

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Hypoxia-Responsive Aggregation of Iron Oxide Nanoparticles for T1-to-T2 Switchable Magnetic Resonance Imaging of Tumors